PMI Q2 2026 Earnings Preview: ZYN Growth, FDA Milestone and What to Expect

Philip Morris International reports its Q2 2026 earnings on Wednesday July 22 at 7:00 AM ET — and for anyone tracking the nicotine pouch market, this is the most important quarterly data point of the year so far. ZYN is the world's largest nicotine pouch brand by volume and PMI's fastest-growing product line. After a turbulent Q1 that saw US shipments drop 23.5% due to inventory destocking — while actual consumer demand quietly grew 10% — Q2 2026 should tell us whether the normalization is complete and how ZYN's landmark FDA MRTP authorization from June 30 is starting to reshape market dynamics. Here's what to expect and what it means for the broader nicotine pouch industry.

Where ZYN Stands After Q1 2026

PMI's Q1 2026 results, reported April 22, told a story of two ZYN narratives happening simultaneously. In the US, shipment volumes fell 23.5% to 155 million cans — a headline figure that alarmed some observers. But PMI's CFO Emmanuel Babeau was clear on the earnings call: this was an inventory normalization event, not a demand collapse. Retailers had built roughly 40 million excess cans of inventory in Q1 2025 and spent Q1 2026 working through that surplus. When adjusted for the inventory correction, PMI estimated the underlying shipment volume consistent with actual consumer demand was approximately 175 million cans.

Consumer offtake — measured by Nielsen retail scan data — grew approximately 10% year-over-year in Q1 2026. Americans are buying and using more ZYN pouches than ever. The supply chain was simply catching up to reality. PMI guided for full-year 2026 US ZYN volumes of 630–680 million cans, implying an average of approximately 158–170 million cans per quarter for Q2–Q4, with some seasonal front-loading in summer. According to reporting by CSP Daily News covering PMI's Q1 earnings, the inventory adjustment was consistent with PMI's earlier guidance and the company maintained its full-year outlook.

Outside the US, the picture was even stronger: international ZYN volumes (excluding Nordic markets) more than doubled in Q1 2026. UK growth has been particularly dramatic — ZYN UK grew over 400% between December 2024 and December 2025, a rate that shows no signs of materially slowing. The EU remains a largely untapped frontier given the product's current grey-market status in most member states, but UK, Switzerland and select markets continue to demonstrate what mainstream acceptance looks like.

The June 30 Moment: ZYN FDA MRTP Authorization

The most consequential regulatory event for the nicotine pouch category in years arrived on June 30, 2026: the FDA authorized 20 ZYN products as Modified Risk Tobacco Products (MRTP). This is not a marketing badge or a certification — it is an FDA legal authorization to make specific, scientifically substantiated claims about reduced health risk compared to cigarettes. According to the FDA's official announcement, ZYN is now authorized to market its products as posing lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to cigarettes.

No other nicotine pouch brand has MRTP authorization in the United States. This is a significant competitive moat for ZYN specifically and for Swedish Match / PMI broadly. It enables a new category of marketing — particularly to cigarette smokers considering switching — that competitors simply cannot legally replicate without their own MRTP authorization (a multi-year regulatory process). The full commercial impact of the MRTP authorization will only start appearing in H2 2026 data, as the authorization came on June 30 and Q2 marketing campaigns will reflect only the final week. The real story will be Q3 and Q4 2026.

What Q2 2026 Should Show: The Analyst View

According to a Nasdaq announcement of the PMI Q2 2026 webcast and aggregated analyst forecasts, the consensus expectation for PMI Q2 2026 is:

• Revenue: $10.56 billion (up year-over-year)
• Adjusted EPS: $2.04 (up 6.8% from Q2 2025's $1.91)
• Key ZYN watch items: Shipment volume recovery, US consumer offtake growth rate continuation, international volume trajectory
• PMI full-year guidance: 5–7% organic net revenue growth; high-single-digit smoke-free volume expansion

Analysts describe the Q2 report as a critical normalization checkpoint. If US ZYN shipments come in at 165–185 million cans (the range consistent with PMI's full-year guidance and underlying demand trajectory), the inventory story will be confirmed as resolved. Any reading significantly below 165M would raise questions about whether destocking is continuing into Q2; any reading above 190M would be a genuine positive surprise suggesting accelerating demand recovery.

A key additional variable in Q2 2026 is the PMI non-cash impairment charge of approximately $500 million related to its Canadian subsidiary RBH, announced in early June 2026 — this will affect reported EPS but not adjusted EPS, and is explicitly excluded from PMI's core operating guidance. Investors tracking ZYN should focus on adjusted metrics and smoke-free product volume data rather than the headline reported figures.

International Expansion: The Growth Story Beyond the US

While US market dynamics dominate ZYN coverage, the international growth narrative is arguably more important for the next 5 years. ZYN volumes outside the US and Nordic markets more than doubled in Q1 2026. The UK, Ireland, Australia (where a grey market exists despite the formal prescription requirement), continental Europe via online retailers, and emerging markets in Eastern Europe are all contributing to what PMI has described as "sustained high-single-digit smoke-free volume expansion."

The EU's regulatory environment remains complex — ZYN is not authorized for sale in most EU member states as a consumer product, but online cross-border orders remain a significant revenue source. The EU TPD3 consultation closing in August 2026 will shape the regulatory trajectory for 2027–2029, but current market growth is happening largely independent of that process. For international growth visibility, Q2 2026 data should include a more granular breakdown of geographic volumes than Q1 — watch for specific mention of UK, Switzerland, and aggregate European volumes in PMI's earnings presentation.

What This Means for Nicotine Pouch Consumers

Earnings season is not only for investors. The PMI Q2 report has direct implications for pouch users:

• Availability: ZYN's continued strong performance means supply constraints seen in late 2024 are firmly in the past. The supply chain is normalized and product availability is consistent across retail and online channels.
• Competition driving prices: PMI's full-year guidance notes "an uneven competitive landscape" in the US — with VELO (BAT), Rogue and others competing actively. This competitive pressure benefits consumers through better pricing and more options.
• The FDA MRTP impact on trust: For users who switched from cigarettes, the FDA's MRTP authorization provides formal, legally validated confirmation that ZYN represents a reduced-risk choice. This matters for hesitant ex-smokers still on the fence about switching.
• ALP's arrival: The July 2026 European launch of ALP (backed by Turning Point Brands and with Conor McGregor as EU ambassador) adds a new premium competitor to the EU market that could drive further innovation and pricing competition in H2 2026.

The Full Picture: Nicotine Pouches in 2026

Zoom out from the quarterly numbers and the trajectory is clear. The global nicotine pouch market sold approximately 34 billion pouches in 2025 — a 660% increase from 2020's baseline of 4.5 billion — and is projected to reach $25 billion in market value by 2028. ZYN alone sells more than half a billion cans annually in the US. In Iceland, nicotine pouches are now the most popular nicotine product, used by more adults daily than cigarettes. The UK saw ZYN grow 400% in a single year. The category is not in a phase of experimental growth — it is scaling into a mainstream consumer product category with the institutional validation to match.

Whether or not PMI beats or misses the Q2 2026 consensus, the structural story for nicotine pouches remains unchanged. The FDA MRTP is a durable competitive advantage. International markets are growing double-digits or better. The regulatory trend, while bumpy in some EU states, is moving toward structured legal frameworks rather than outright bans in most key markets. Explore the full current ZYN range at The Snus Outlet — available in every strength and flavour with fast EU delivery on orders over €99.

Frequently Asked Questions

When does PMI report Q2 2026 earnings?

Philip Morris International reports Q2 2026 results on Wednesday July 22, 2026 at approximately 7:00 AM ET, before the US market opens. A live investor webcast follows at 9:00 AM ET. The report includes detailed ZYN shipment volumes, revenue breakdown, and updated full-year guidance. You can follow the PMI investor relations page at pmi.com for real-time updates.

What is ZYN's FDA MRTP authorization?

On June 30, 2026, the FDA authorized 20 ZYN products as Modified Risk Tobacco Products — the first nicotine pouches ever to receive this status. The authorization permits ZYN to market its products as posing lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis compared to cigarettes. This is a legally substantiated claim backed by a full FDA scientific review, not a marketing assertion. No other nicotine pouch brand currently holds MRTP authorization in the US.

Why did ZYN US shipments fall in Q1 2026?

ZYN US shipments fell 23.5% to 155 million cans in Q1 2026 due to inventory normalization — retailers worked through excess stock built up in Q1 2025. Consumer demand (measured by Nielsen offtake data) actually grew approximately 10% in the same period. PMI estimated the underlying demand-consistent shipment volume was around 175 million cans. The Q2 2026 report will confirm whether destocking is complete.

What nicotine pouch brands compete with ZYN?

ZYN's primary competitors include VELO (British American Tobacco), Rogue (in the US), LOOP, XQS, ZEUS, C.R.E.A.M, and the newly launched ALP (Turning Point Brands, EU July 2026 launch). In Europe, The Snus Outlet stocks the full competitive range — browse the best nicotine pouches of 2026 for a side-by-side comparison across every brand.

Final Thoughts

Tomorrow's PMI Q2 2026 report is not just a corporate earnings release — it's the latest chapter in one of the most significant consumer product category shifts of the decade. ZYN's trajectory, the FDA MRTP milestone, and the continued explosion of international adoption collectively point to a category that is past its inflection point and into mainstream scale. The inventory noise of Q1 should clear by Q2; the MRTP marketing strategy starts in earnest in H2 2026; and the competitive landscape, while more crowded than two years ago, continues to grow the overall category faster than any individual brand loses share.

Stay ahead of the market at The Snus Outlet — the full 2026 range across ZYN, VELO, LOOP, XQS, ZEUS, C.R.E.A.M and KUMA, with fast EU delivery on all orders over €99.